A new study underway at St. David’s Surgical Hospital could help men recover faster and live a better quality of life after ...

Prostate cancer survivors Mark V. Williamson and Jim East will celebrate with other men who beat the disease, Nov. 16 at the ...

Fresh from a European cancer conference that was all about antibody-drug conjugates (ADCs), GSK has turned to French biotech ...

NICE recommends Bayer’s Nubeqa® (darolutamide) plus androgen deprivation therapy as a treatment option for patients with hormone-sensitive metastatic prostate cancer Nubeqa® (darolutamide) plus ...

The National Institute for Health and Care Excellence (NICE) has recommended darolutamide in combination with androgen ...

GSK has acquired the rights to Syndivia’s preclinical antibody drug conjugate (ADC), which is in development for prostate ...

The combination of niraparib and abiraterone halves the spread of prostate cancer in men with BRCA gene mutations.

(Alliance News) - GSK PLC on Monday announced an agreement with Syndivia that grants GSK exclusive worldwide rights to develop and commercialise a preclinical antibody-drug conjugate for metastatic ...

GSK (GSK) announced an agreement granting GSK exclusive worldwide rights to develop and commercialise a preclinical ADC for mCRPC. The novel ADC, ...